Sarcopenia and Osteoporosis

Abstract

Osteoporosis and sarcopenia are major health issues which are going to have a significant impact in an aging global population. Osteoporosis, which reduces bone density and increases fracture risk, and sarcopenia, which causes muscle loss and strength loss, have a complicated risk profile with consequences that go beyond bone and muscle health. This chapter illuminates the complex link between osteoporosis and sarcopenia, including overlapping causes, clinical consequences, and new treatments. This chapter covers bone and muscle biology, age-related changes that cause osteoporosis and sarcopenia, and the importance of physical exercise and diet in their prevention and management. It also discusses clinical evaluation methods, risk assessment and diagnostic criteria for early diagnosis and intervention. Novel therapies and continuing research in the management of osteoporosis and sarcopenia are also discussed. Medications, exercise, and nutrition can promote bone and muscle health. This chapter aims to explore the recent concepts by elucidating the complex relationship between osteoporosis and sarcopenia and advocating for integrated care paradigms.

Introduction

Osteoporosis and sarcopenia are two age-related conditions that have significant implications for health and quality of life, particularly among older adults. Osteoporosis is characterized by a reduction in bone mass and deterioration of bone tissue, leading to increased susceptibility to fractures. On the other hand, sarcopenia refers to the progressive loss of skeletal muscle mass, strength, and function.

Definition and Prevalence of Osteoporosis

Osteoporosis is defined as a skeletal disorder characterised by compromised bone strength, which predisposes individuals to an increased risk of fractures. The World Health Organization (WHO) established the definition of osteoporosis as a bone mineral density that is less than 2.5 standard deviations below the sex-specific young adult mean in 1994 [1]. This definition has since been widely accepted. Bone mineral density has been included into algorithms for predicting fracture risk, such as the WHO-developed Fracture Risk Assessment Tool (FRAX^®). Reduced bone density and structural integrity happen in osteoporosis when the rate of bone resorption exceeds the rate of bone creation. Osteoporotic fractures, most commonly affecting the hip, spine, and wrist, are a major health concern due to their associated morbidity, mortality, and healthcare costs.

The prevalence of osteoporosis varies worldwide, with higher rates observed in postmenopausal women and the elderly. In many populations, increased prevalence of osteoporosis is expected due to ageing populations and changing lifestyles. Over 200 million people are thought to be afflicted by osteoporosis globally, and the figure is expected to rise sharply in the future years.

Definition and Prevalence of Sarcopenia

The term sarcopenia was coined by Irwin Rosenberg in 1989 [2]. The European Working Group on Sarcopenia in Older People (EWGSOP) first defined sarcopenia in 2010 [3]. In 2018, they met again (EWGSOP2) and produced an operational definition [4]. The presence of the following was defined as sarcopenia:

• (i)Low muscle strength,
• (ii)Low muscles quantity and quality and
• (iii)Low physical performance.

Presence of one criteria is probable sarcopenia, presence of two criteria confirms diagnosis and if all three are present, it is considered severe sarcopenia. Sarcopenia may be acute or chronic. Sarcopenia is more common in some communities than others, with rates between 5% and 50% in those over 65 [5, 6]. These variances rely on factors including the precise methods employed to gauge muscle mass and function, the research population, and diagnostic standards. By the seventh decade of life, sarcopenia affects 5–13% of people, and by the age of 80, it can affect 11–50%. Furthermore, it is estimated that by 2050, it will have an impact on more than 500 million senior individuals. The progressive and widespread skeletal muscle affliction known as sarcopenia is typified by the normal ageing-related decrease in muscular mass, strength, and function. It happens when the breakdown and synthesis of muscle proteins are out of balance, which causes the muscle tissue to progressively deteriorate. Sarcopenia can impair physical performance, reduce functional independence, and increase the risk of falls and fractures. The condition is more common in older adults, particularly those who are sedentary or have multiple chronic conditions. Sarcopenia has substantial implications for overall health, as it is associated with increased disability, higher healthcare utilization, and reduced quality of life [2, 7].

The Impact of Osteoporosis and Sarcopenia on Health and Quality of Life

Both osteoporosis and sarcopenia have significant consequences for health and well-being. Osteoporotic fractures can lead to severe pain, disability, and functional limitations. They often require hospitalization, surgical interventions, and prolonged rehabilitation. Fractures in older individuals can have long-term consequences, such as decreased mobility, increased dependency on others, and a higher risk of subsequent fractures.

Similarly, sarcopenia can have detrimental effects on physical function, leading to difficulties in performing daily activities, reduced mobility, and increased vulnerability to falls. Frailty, impairment, and loss of independence can all emerge as a result of muscle mass and strength loss.

Moreover, osteoporosis and sarcopenia often coexist and interact synergistically, creating a vicious cycle of bone and muscle deterioration. The combination of reduced bone density and muscle weakness further increases the risk of falls, fractures, and functional decline [7].

In contrast, Sarcopenia is diagnosed by reduced muscle mass and muscular function. However, the criteria are not widely recognised.

Frailty

Experts agree that it is a clinical condition characterised by increased vulnerability and impaired resistance to stresses that may impair functioning and increase dangers, despite the lack of a universal description [8]. Sarcopenia is the main condition behind frailty, and persons who exhibit at least three of the following symptoms—unintentional weight loss, exhaustion, weakness, slowness, and restricted physical activity—are considered to be frail.

Bone Health and Osteoporosis

Bone Structure and Function

Bone is a dynamic and living tissue that plays a vital role in supporting the body, protecting organs, and facilitating movement. It consists of a complex structure comprising both mineralized components, such as hydroxyapatite crystals, and organic components, including collagen fibers and various cells.

The main functions of bone include providing structural support, allowing movement through its articulations with muscles, storing minerals, such as calcium and phosphorus, and producing blood cells within the bone marrow. Through a balanced process of bone creation by osteoblasts and bone resorption by osteoclasts, bone is continuously remodelled.

Normal Bone Remodelling Process

Bone remodelling is a continuous and tightly regulated process that ensures the maintenance of bone strength and integrity throughout life. It involves the coordinated activities of osteoblasts and osteoclasts, under the influence of various signalling molecules and hormones.

Osteoblasts are responsible for synthesizing and depositing new bone tissue, whereas osteoclasts are specialised cells that break down and resorb old or damaged bone. The elimination of old bone and the formation of new bone are made possible by this dynamic equilibrium between bone creation and resorption, which preserves the strength and structure of the skeleton.

Pathophysiology of Osteoporosis

When bone creation and resorption are out of balance, osteoporosis develops. This results in a loss of bone mass and a degradation of the bone's microarchitecture. This imbalance may be due to various factors, including hormonal changes, nutritional deficiencies, genetic predisposition, and lifestyle factors.

The most prevalent type, postmenopausal osteoporosis, is predominantly caused by oestrogen insufficiency in women following menopause. By preventing bone resorption and encouraging bone growth, oestrogen maintains bone density. Other forms of osteoporosis can result from secondary causes, such as chronic diseases, certain medications, or hormonal disorders. The scope of this chapter does not allow for a thorough discussion of the pathophysiology of osteoporosis.

Risk Factors for Osteoporosis

Osteoporosis develops as a result of a number of risk factors. Age, female gender, family history of osteoporosis, and other genetic variables are among the risk factors that cannot be changed and are called non-modifiable. Low calcium and vitamin D intake, a sedentary lifestyle, cigarette smoking, excessive alcohol use, and long-term use of drugs such as corticosteroids are all modifiable risk factors [9].

Diagnostic Methods for Osteoporosis

Dual-energy X-ray absorptiometry (DXA), which measures bone mineral density (BMD), is frequently used to diagnose osteoporosis. DXA scan generates the T score which compares the person’s BMD with that of a healthy young adult reference population. This gives an idea of the amount of bone lost. For screening or monitoring purposes, other imaging modalities, such as quantitative ultrasonography and peripheral DXA, may be utilised.

Clinical Manifestations and Complications of Osteoporosis

Osteoporosis is also called a “silent disease”, because it progresses silently without causing noticeable symptoms until a fracture occurs. Fractures, especially in the spine, hip, and wrist, are the most significant clinical manifestations of osteoporosis. These fractures can cause severe pain, deformity, reduced mobility, and loss of functional independence. In addition, osteoporotic fractures are associated with increased morbidity, mortality, and healthcare costs.

Muscle Health and Sarcopenia

Muscle Tissue and Its Role in the Body

Muscle tissue is a highly specialised type of soft tissue that plays a crucial role in maintaining body structure, facilitating movement, and supporting various metabolic processes. It is composed of bundles of muscle fibres, each containing myofibrils comprised of the contractile proteins actin and myosin.

Muscles are responsible for generating force and enabling movement through the coordinated contraction and relaxation of muscle fibres. They are classified into three types: skeletal muscles, which are responsible for voluntary movements; smooth muscles, found in organs and blood vessels, enabling involuntary functions; and cardiac muscles, which make up the heart and regulate its contractions.

Age-Related Changes in Muscle Mass and Function

As age increases, the muscle mass, strength, and function reduce. This age-related loss of muscle tissue is known as sarcopenia. It is primarily attributed to a combination of factors, including reduced muscle protein synthesis, increased protein breakdown, hormonal changes, and oxidative stress.

Sarcopenia affects both the size and number of muscle fibres, which results in a reduction of muscle mass. In addition, there is a decline in muscle quality, characterized by a decrease in muscle strength, power, and endurance. These changes can lead to functional limitations, decreased mobility, and an increased risk of falls and fractures.

Pathophysiology of Sarcopenia

Sarcopenia is caused by multiple factors and involves a complex interplay of biological, hormonal, and lifestyle factors. It is influenced by factors, such as chronic inflammation, hormonal changes (including reduced levels of testosterone and growth hormone), impaired muscle protein synthesis, mitochondrial dysfunction, and altered neuromuscular signalling.

The age-related decline in anabolic hormones and increased pro-inflammatory cytokines contribute to the disruption of muscle homeostasis and the loss of muscle mass and function. The progressive imbalance between muscle protein synthesis and breakdown leads to a net loss of muscle tissue over time.

According to a study, reactive oxygen species (ROS) are other key components whose overexpression adversely impacts mitochondrial function and results in myosteatosis, a condition in which adipose tissue accumulates in skeletal muscle. The downregulation of satellite cells brought on by an increase in FGF2 and a reduction in FGF6 leads to yet another breakdown of muscle tissue [10].

Risk Factors for Sarcopenia

Several risk factors contribute to the development and progression of sarcopenia. Advanced age is the primary risk factor, with the prevalence of sarcopenia increasing significantly after the age of 60. Other factors include a sedentary lifestyle, inadequate nutrition, chronic diseases (such as diabetes and cardiovascular diseases), certain medications (such as glucocorticoids), and hormonal imbalances [6, 11].

Diagnostic Methods for Sarcopenia

Diagnosing sarcopenia typically involves the assessment of muscle mass, strength, and physical performance. Imaging techniques, such as the dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (CT), and magnetic resonance imaging (MRI), can measure muscle mass and identify changes in muscle composition. Grip strength and muscle power assessments are commonly used to evaluate muscle strength. Functional tests, such as gait speed and chair stands, provide information about physical performance and functional limitations [8, 12].

Clinical Manifestations and Complications of Sarcopenia

Sarcopenia is associated with a range of clinical manifestations and complications. Individuals with sarcopenia often experience muscle weakness, reduced muscle endurance, and decreased physical performance. These changes can impair mobility, balance, and coordination, increasing the risk of falls and fractures. Sarcopenia is also associated with increased morbidity, hospitalisation rates, and healthcare utilization.

Inter-relationship Between Osteoporosis and Sarcopenia

Shared Risk Factors and Mechanisms

Osteoporosis and sarcopenia often share common risk factors and underlying mechanisms [2, 7, 13] (Fig. 1). Age-related hormonal changes, chronic inflammation, and inadequate nutrition can contribute to both conditions. For instance, reductions in oestrogen and testosterone levels during ageing can affect both bone density and muscle mass. Inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), have been implicated in the pathogenesis of both osteoporosis and sarcopenia [7].

Fig. 1.

Inter-relationship between muscle and bone

In addition, lifestyle factors, such as physical inactivity and poor nutrition, including inadequate protein intake and vitamin D deficiency, can negatively impact both bone health and muscle mass. The interplay of these shared risk factors highlights the importance of a holistic approach to addressing both osteoporosis and sarcopenia.

Impact of Sarcopenia on Bone Health and Vice Versa

Sarcopenia can have direct and indirect effects on bone health. The loss of muscle mass and strength reduces mechanical loading on the bones, leading to decreased bone mineral density and impaired bone remodelling. In addition, muscle–bone crosstalk is an essential regulatory mechanism, where muscle-derived factors, such as myokines, influence bone metabolism. Therefore, the decline in muscle mass associated with sarcopenia can disrupt this regulatory interaction and contribute to bone loss.

Conversely, osteoporosis and fractures can exacerbate sarcopenia. Fractures often result in reduced physical activity and immobilization, leading to muscle disuse and further muscle loss. Pain and limited mobility associated with fractures can also hinder participation in physical activities and exercise, accelerating the progression of sarcopenia. Many studies have found an positive association between these two conditions.

Combined Effects on Physical Function and Mobility

The coexistence of osteoporosis and sarcopenia has a synergistic effect on physical function and mobility. Both conditions individually impair musculoskeletal function, and their combined effects can result in greater functional limitations, reduced mobility, and an increased risk of falls and fractures.

Muscle strength is a crucial determinant of balance and postural control, which are vital for maintaining stability during various activities. In the presence of both osteoporosis and sarcopenia, compromised bone strength and reduced muscle function synergistically contribute to an increased risk of falls and fractures. This can further exacerbate the cycle of functional decline, as fractures can lead to prolonged immobilisation and muscle disuse [8, 14, 15].

Clinical Implications and Challenges in Management

The inter-relationship between osteoporosis and sarcopenia has significant clinical implications. It highlights the importance of considering both bone health and muscle mass and function in the assessment and management of individuals at risk. Screening and diagnostic tools should evaluate both conditions to provide a comprehensive assessment of musculoskeletal health.

Challenges in managing osteoporosis and sarcopenia together include developing integrated interventions that address both conditions simultaneously. Strategies aimed at improving bone health, such as pharmacological interventions and lifestyle modifications, should be combined with interventions targeting muscle mass, strength, and function, such as resistance training and nutritional optimization.

In addition, the identification and management of shared risk factors, such as hormonal deficiencies and nutritional deficiencies, should be addressed comprehensively. Collaborative efforts between healthcare professionals specializing in bone health and geriatric medicine, as well as multidisciplinary approaches involving exercise physiologists, dietitians, and physical therapists, are essential for optimising outcomes in individuals with both osteoporosis and sarcopenia.

Clinical Assessment and Treatment Guidelines

Clinical Assessment of Osteoporosis

Accurate clinical assessment is essential for the diagnosis and management of osteoporosis. The assessment typically includes the following components:

Medical history A comprehensive review of medical history aids in the identification of risk factors such past fractures, comorbidities, family history of osteoporosis, prescription usage (such as glucocorticoids), and lifestyle choices (such as smoking and binge drinking).

Physical examination A physical examination may reveal signs of height loss, kyphosis (excessive forward curvature of the spine), and other skeletal abnormalities associated with osteoporosis.

BMD measurement Dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring BMD. It is used to assess the bone density at the hip, spine, or forearm and aids in the diagnosis of osteoporosis and the determination of fracture risk.

Laboratory tests Blood tests are performed to assess calcium, vitamin D, parathyroid hormone (PTH), and other relevant parameters that may impact bone health.

Clinical Assessment of Sarcopenia

The clinical assessment of sarcopenia involves evaluating muscle mass, muscle strength, and physical performance. Common assessment tools include:

Dual-energy X-ray absorptiometry (DXA) Appendicular lean mass (ALM), a marker of muscle mass, may be measured with DXA.

Grip strength Handgrip strength is a quick and accurate indicator of total muscular power and is linked to functional restrictions and impairment.

Timed up and go (TUG) test The TUG test determines how long it takes someone to stand up from a chair, move 3 m, turn around, and then sit back down. It evaluates physical performance and mobility.

Other functional tests Additional functional tests, such as the 6-min walk test or the short physical performance battery (SPPB), may be used to evaluate physical performance and functional status.

For the estimation of total or Appendicular Skeletal Mass (ASM), bioelectrical impedance analysis (BIA) has been investigated. BIA technology estimates muscle mass based on whole-body electrical conductivity rather than directly measuring muscle mass.

The SARC-F questionnaire should be used in clinical settings to detect or test for individuals who may have sarcopenia, according to EWGSOP2 [4]. In addition to using DXA and BIA procedures, they advocate using chair stands and grip strength tests to assess weak muscle strength and for general clinical treatment. For research and specialist care for individuals at high risk of adverse outcomes, DXA, MRI, or CT are also advised. DXA, BIA, or MRI are also advised for measuring muscle and confirming the diagnosis of sarcopenia.

Treatment Guidelines for Osteoporosis

The primary aims in the management of osteoporosis are to reduce fracture risk, improve bone health, and manage underlying conditions contributing to bone loss [8, 11, 14–16]. Treatment guidelines typically recommend the following:

Calcium and vitamin D supplementation Adequate calcium and vitamin D intake are essential for maintaining bone health. Supplementation is recommended if dietary intake is insufficient.

Lifestyle modifications Regular weight-bearing exercises, muscle-strengthening activities, and balance training are encouraged to improve bone density and muscle strength. Smoking cessation and moderation of alcohol intake are also advised.

Pharmacological interventions For those who are at a high risk of fracture, pharmaceutical therapy is advised. Depending on a patient's risk factors and preferences, medical practitioners may prescribe drugs such selective oestrogen receptor modulators (SERMs), bisphosphonates, denosumab, and teriparatide.

Treatment Guidelines for Sarcopenia

Management of sarcopenia primarily focuses on preserving and improving muscle mass, strength, and physical function. While specific pharmacological treatments for sarcopenia are limited, the following approaches are commonly recommended:

Resistance training Progressive resistance training, involving exercises with weights or resistance bands, is considered the cornerstone of sarcopenia management. It promotes muscle protein synthesis and enhances muscle strength and mass [8, 15, 17].

Nutritional optimization Adequate protein intake is crucial for muscle health. Consuming high-quality protein sources throughout the day, along with a balanced diet, supports muscle maintenance and repair.

Vitamin D supplementation Elderly people frequently lack vitamin D, which can have a detrimental effect on how well their muscles work. It is frequently recommended to take supplements to keep one's vitamin D levels at a healthy level.

Multidisciplinary approach Collaborative efforts between healthcare professionals, including physicians, physical therapists, and dietitians, can optimise treatment strategies and address individual needs.

It's important to note that treatment guidelines may vary across regions and organizations, and individualised care based on patient characteristics and preferences is essential.

Prevention and Management Strategies

Lifestyle Modifications

Lifestyle modifications play a crucial role in the prevention and management of osteoporosis and sarcopenia [5, 8, 14, 15]. Regular weight-bearing and resistance exercises are beneficial for both bone health and muscle mass. Weight-bearing exercises, such as walking, jogging, and dancing, help stimulate bone remodelling and promote bone density. Resistance exercises, such as lifting weights or using resistance bands, are effective in preserving and building muscle strength and mass.

Adequate nutrition is essential for maintaining bone health and muscle function. Consuming a balanced diet rich in calcium, vitamin D, and protein is important for supporting bone mineralization and muscle protein synthesis. Calcium-rich foods include dairy products, leafy greens, and fortified foods. Vitamin D can be obtained through sunlight exposure and dietary sources, such as fatty fish and fortified products. Protein-rich foods, such as lean meats, poultry, fish, legumes, and dairy products, provide essential amino acids for muscle maintenance and repair.

Pharmacological Interventions

To lower the risk of fractures, pharmacological therapies are frequently used in the management of osteoporosis. To increase bone density and lower the risk of fractures, medications including bisphosphonates, selective oestrogen receptor modulators (SERMs), and denosumab are frequently recommended. These drugs work by preventing bone resorption or by encouraging bone creation. On the basis of individual risk factors, potential side effects, and medical history, their usage should be carefully examined.

While there are currently no specific pharmacological treatments approved for sarcopenia, certain medications and supplements, such as anabolic agents, testosterone, and vitamin D, may be considered in selected cases. However, further research is needed to establish their efficacy and safety in the management of sarcopenia.

Fall Prevention Strategies

Given the increased risk of falls and fractures associated with osteoporosis and sarcopenia, fall prevention strategies are crucial in reducing morbidity and maintaining independence. These strategies include:

Environmental modifications Ensuring a safe living environment by removing tripping hazards, installing handrails and grab bars, and improving lighting conditions.

Balance and strength training Participating in exercises that improve balance, coordination, and muscle strength, such as tai chi, yoga, and specific balance exercises.

Vision assessment Regular eye examinations to address visual impairments that may contribute to falls.

Medication review Reviewing medications to identify any that may increase the risk of falls or dizziness and discussing potential alternatives with healthcare providers.

Multidisciplinary Approach

The management of osteoporosis and sarcopenia often requires a multidisciplinary approach involving healthcare professionals from various specialties. Collaborative efforts among physicians, nurses, physical therapists, dietitians, and exercise specialists can optimise outcomes and provide comprehensive care.

Regular monitoring and follow-up are essential to assess treatment efficacy, adjust interventions as needed, and address any potential side effects or complications.

Health Education and Awareness

Promoting health education and raising awareness about osteoporosis and sarcopenia are key to preventing and managing these conditions. Educating individuals about the importance of bone health, muscle-strengthening exercises, adequate nutrition, fall prevention strategies, and the benefits of early detection and intervention can empower them to take proactive steps toward maintaining musculoskeletal health.

Providing educational resources, community programs, and support groups can also enhance awareness and encourage individuals to adopt healthy lifestyles and seek appropriate care.

By implementing a combination of lifestyle modifications, pharmacological interventions when indicated, fall prevention strategies, and a multidisciplinary approach, the prevention and management of osteoporosis and sarcopenia can be effectively addressed, promoting optimal musculoskeletal health and overall well-being.

Future Directions and Research

Advancements in Diagnostic Tools

The field of osteoporosis and sarcopenia research continues to evolve, with ongoing advancements in diagnostic tools. Innovations in imaging techniques, such as high-resolution peripheral quantitative computed tomography (HR-pQCT) and magnetic resonance imaging (MRI), offer improved assessment of bone microarchitecture and muscle quality. These advanced imaging modalities provide a more detailed understanding of structural changes in bone and muscle, aiding in early detection and personalised treatment approaches.

Emerging Therapies and Interventions

Research efforts are focused on developing novel therapies and interventions for osteoporosis and sarcopenia. Targeted approaches, such as the use of specific bone-forming agents or muscle-building compounds, are being explored to enhance bone and muscle health. In addition, regenerative medicine strategies, including stem cell therapy and tissue engineering, hold promise to promoting tissue regeneration and functional recovery.

Personalized Medicine and Precision Interventions

The concept of personalised medicine and precision interventions is gaining traction in the field of musculoskeletal health. Genetic profiling, biomarker assessment, and molecular diagnostics are being investigated to identify individuals at higher risk for osteoporosis and sarcopenia. This knowledge can guide the development of tailored interventions, including customised exercise programs, nutrition plans, and pharmacological treatments, to optimise outcomes based on individual characteristics and needs.

Combination Therapies and Synergistic Approaches

Given the inter-relationship between osteoporosis and sarcopenia, combination therapies and synergistic approaches are being explored. Integrated interventions that simultaneously target both conditions show potential for improved outcomes. For example, exercise programmes that incorporate both weight-bearing activities for bone health and resistance training for muscle strength can have synergistic effects on overall musculoskeletal health.

Technology-Based Interventions

Advancements in technology offer opportunities for innovative interventions in the management of osteoporosis and sarcopenia. Virtual reality, wearable devices, and mobile applications can facilitate remote monitoring, deliver personalised exercise programs, and provide real-time feedback on exercise technique and adherence. These technological interventions have the potential to enhance engagement, improve treatment compliance, and expand access to care.

Long-Term Outcomes and Quality of Life

Future research should focus on assessing long-term outcomes and quality of life in individuals with osteoporosis and sarcopenia. Understanding the impact of these conditions on overall well-being, including physical function, independence, and psychological aspects, is crucial for comprehensive management. Research exploring the effects of interventions on functional outcomes, fracture rates, hospitalizations, and healthcare costs will contribute to evidence-based practice and inform healthcare decision-making.

By advancing diagnostic tools, exploring emerging therapies, embracing personalised medicine approaches, investigating combination therapies, leveraging technology-based interventions, and prioritising long-term outcomes and quality of life, the field of osteoporosis and sarcopenia research is poised for significant advancements in the coming years.

Osteosarcopenia and COVID-19

The co-existence of osteoporosis and sarcopenia, which share the same clinical and biochemical characteristics, is known as osteosarcopenia. Due to prolonged hospital stays, death, intensive care unit admission, the requirement for invasive mechanical ventilation, and poor rehabilitation results, sarcopenia has become a predictor of poor outcomes in COVID-19 patients. The link between sarcopenia and COVID-19 patients' poor outcomes may be caused by chronic inflammation, immunological dysfunction, respiratory muscle failure, and swallowing dysfunction [18–20].

Conclusion

Osteoporosis and sarcopenia are two common age-related conditions that significantly impact musculoskeletal health, functional independence, and quality of life. Their inter-relationship, shared risk factors, and combined effects on physical function highlight the importance of a comprehensive approach in their assessment and management.

Understanding the pathophysiology, diagnostic methods, clinical manifestations, and complications of osteoporosis and sarcopenia is crucial for early detection and intervention. By implementing preventive measures, such as lifestyle modifications and fall prevention strategies, individuals can reduce their risk of developing these conditions and mitigate their impact.

Healthcare providers play a vital role in identifying individuals at risk, performing comprehensive assessments, and developing personalised management plans. A multidisciplinary approach involving collaboration among healthcare professionals from various specialties ensures holistic care and optimal outcomes.

Advancements in diagnostic tools, emerging therapies, personalised medicine approaches, and technology-based interventions offer promising avenues for the future. Continued research and innovation will contribute to improved strategies for prevention, early detection, and effective management of osteoporosis and sarcopenia.

By promoting awareness, educating individuals, and implementing evidence-based interventions, we can work towards reducing the burden of these conditions and enhancing musculoskeletal health across the lifespan.

In conclusion, osteoporosis and sarcopenia are complex conditions that require a comprehensive approach for their prevention and management. By addressing their inter-relationship, adopting a multidisciplinary approach, and embracing advancements in research and technology, we can make significant strides in promoting musculoskeletal health and improving the overall well-being of individuals affected by these conditions.

Declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed Consent

For this type of study, informed consent is not required.